Intranasal Peptide Delivery Compositions and Methods
Summary
USPTO published patent application US20260108583A1, filed March 4, 2025, covering compositions and methods for intranasal delivery of therapeutic peptides. Inventors Spencer Bouhadir and Jacob J. Miguel are listed. CPC classifications include A61K 38/05, A61K 9/0043, A61K 9/107, A61K 47/38, and A61K 47/6951, indicating peptide-based pharmaceutical formulations for intranasal administration. The application has entered the published phase of USPTO examination.
“The present disclosure provides, inter alia, compositions and methods for intranasal delivery of peptides.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108583A1 for intranasal peptide delivery technology, filed March 4, 2025, and made publicly available on April 23, 2026. The application claims compositions and methods for delivering therapeutic peptides via the intranasal route. CPC classifications indicate focus on peptide drugs (A61K 38/05) in nasal delivery formats (A61K 9/0043, A61K 9/107) with specific excipient formulations (A61K 47/38, A61K 47/6951).
For pharmaceutical and biotechnology companies developing peptide-based therapeutics, this published application establishes a prior art reference for intranasal delivery methods. Parties pursuing similar delivery technologies should conduct freedom-to-operate analyses and consider design-around strategies. Inventors Bouhadir and Miguel may be relevant for licensing discussions or collaborative development in the nasal peptide delivery space.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES
Application US20260108583A1 Kind: A1 Apr 23, 2026
Inventors
Spencer Bouhadir, Jacob J. Miguel
Abstract
The present disclosure provides, inter alia, compositions and methods for intranasal delivery of peptides.
CPC Classifications
A61K 38/05 A61K 9/0043 A61K 9/107 A61K 47/38 A61K 47/6951
Filing Date
2025-03-04
Application No.
19070362
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.